A detailed history of Axa S.A. transactions in Astrazeneca PLC stock. As of the latest transaction made, Axa S.A. holds 423,192 shares of AZN stock, worth $28.4 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
423,192
Previous 400,242 5.73%
Holding current value
$28.4 Million
Previous $31.2 Million 5.64%
% of portfolio
0.1%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$76.67 - $87.62 $1.76 Million - $2.01 Million
22,950 Added 5.73%
423,192 $33 Million
Q2 2024

Aug 14, 2024

BUY
$66.81 - $80.83 $24.4 Million - $29.5 Million
365,121 Added 1039.61%
400,242 $31.2 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $320,041 - $364,825
5,244 Added 17.55%
35,121 $2.38 Million
Q4 2023

Jul 16, 2024

SELL
$61.89 - $69.28 $324,551 - $363,304
-5,244 Reduced 14.93%
29,877 $2.01 Million
Q4 2023

Feb 14, 2024

BUY
$61.89 - $69.28 $312,915 - $350,279
5,056 Added 20.37%
29,877 $2.01 Million
Q3 2023

Nov 14, 2023

BUY
$64.85 - $71.7 $334,820 - $370,187
5,163 Added 26.26%
24,821 $1.68 Million
Q2 2023

Aug 14, 2023

SELL
$69.91 - $75.81 $489 - $530
-7 Reduced 0.04%
19,658 $1.41 Million
Q4 2022

Feb 14, 2023

BUY
$54.21 - $70.44 $1.07 Million - $1.39 Million
19,665 New
19,665 $1.33 Million
Q1 2022

May 13, 2022

SELL
$55.72 - $67.12 $33,822 - $40,741
-607 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$55.56 - $60.79 $33,724 - $36,899
607 New
607 $36,000
Q1 2021

May 14, 2021

SELL
$47.16 - $54.44 $91,914 - $106,103
-1,949 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$48.52 - $58.02 $3,347 - $4,003
69 Added 3.67%
1,949 $97,000
Q3 2020

Nov 13, 2020

BUY
$53.07 - $61.1 $99,771 - $114,868
1,880 New
1,880 $103,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.